J.W. Burns & Co’s ADMA Biologics ADMA Stock Holding History

J.W. Burns & Co’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-15,250	Closed	-$36K	–	166
2020 Q3	$36K	Sell	15,250 -6,250	-29%	-$17.1K	0.01%	158
2020 Q2	$63K	Hold	21,500	–	–	0.01%	149
2020 Q1	$62K	Buy	21,500 +5,500	+34%	+$19K	0.02%	143
2019 Q4	$64K	Buy	16,000 +1,500	+10%	+$6.54K	0.01%	161
2019 Q3	$65K	Hold	14,500	–	–	0.02%	160
2019 Q2	$56K	Hold	14,500	–	–	0.01%	164
2019 Q1	$55K	Buy	+14,500	New	+$51.3K	0.01%	158

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

J.W. Burns & Co's ADMA Position: Q4 2020 in Review

J.W. Burns & Co sold out of ADMA Biologics (ADMA) in Q4 2020, closing a stake of 15,250 shares — an estimated $36K sold.

J.W. Burns & Co first reported a position in ADMA in Q1 2019 and held it in 7 quarters. The position peaked at $65K in Q3 2019. 95 funds tracked by Wall St. Rank hold ADMA as of Q4 2020.

J.W. Burns & Co reported no remaining ADMA Biologics position as of Q4 2020 after selling out during the quarter.
J.W. Burns & Co sold 15,250 ADMA Biologics shares in Q4 2020, an estimated $36K.
J.W. Burns & Co first reported a position in ADMA Biologics in Q1 2019 and held it in 7 quarters.
J.W. Burns & Co's ADMA Biologics position peaked at $65K in Q3 2019.
95 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2020.

Based on J.W. Burns & Co's 13F filing for Q4 2020, filed 12 Jan 2021.